Soligenix presents at the national foundation for infectious diseases annual conference on vaccinology research

Princeton, n.j., april 28, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its senior vice president and chief scientific officer, oreola donini, phd, delivered a presentation demonstrating the potency of the civax™ (covid-19 vaccine) development program in mice and non-human primates (nhps), at the annual conference on vaccinology research (acvr) on april 26-27, 2021.
SNGX Ratings Summary
SNGX Quant Ranking